Goldman Ups GlaxoSmithKline to 'Outperform'

Analyst Vikram Sahu likes the stock's valuation; he also says the drug maker will be less exposed to generic competition in coming years

Goldman Sachs upgraded GlaxoSmithKline (GSK ) to outperform from in-line.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.